FDA Scientists Raise Red Flags Over Trendy Peptide Therapies Backed by RFK Jr.

FDA Researchers and RFK Jr. Are Pulling in Opposite Directions on Peptides

A growing tension is emerging within the Department of Health and Human Services: while Health Secretary Robert F. Kennedy Jr. champions broader access to peptide therapies, the very scientists who work beneath him are urging caution — and for good reason.

The Food and Drug Administration published a set of documents this week laying out serious reservations about multiple peptide compounds currently under regulatory review. An FDA advisory panel is scheduled to evaluate these substances in a two-day session on July 23 and 24, with further deliberations planned for February.

What Are Peptides and Why Are They Trending?

Peptides are short chains of amino acids — essentially smaller relatives of proteins — that the human body naturally produces. Some of the most commercially successful drugs in recent history, including GLP-1 receptor agonists used for weight loss, fall into this category of synthetic peptides.

However, the peptide products generating buzz in wellness communities are a different story. Promoted heavily by social media influencers and some clinicians, these compounds — including BPC-157, TB-500, and MOTs-C — are marketed for everything from injury recovery and muscle repair to metabolism enhancement and longevity. Most are administered through subcutaneous injections.

Unlike FDA-approved medications, these peptide therapies have never been subjected to large-scale, rigorous human clinical trials.

FDA Scientists Flag Evidence Gaps and Safety Concerns

The internal review documents released by the FDA highlight a consistent lack of reliable data supporting the safety or effectiveness of these compounds. Scientists noted an absence of high-quality evidence and raised concerns about potential health risks.

The Biden administration moved to restrict these peptides back in 2023, placing them in a regulatory category that effectively barred compounding pharmacies from producing them. Since that decision, many users have turned to an unregulated gray market, frequently purchasing products from questionable overseas suppliers — a situation that compounds the safety risks.

RFK Jr.'s Personal Endorsement Fuels the Debate

Secretary Kennedy has been openly vocal about his enthusiasm for peptides, acknowledging personal use of some of these compounds. He has publicly advocated for the FDA — an agency that falls under HHS oversight — to restore compounding pharmacies' ability to formulate and dispense these therapies.

The advisory panel assembled to weigh the evidence has drawn scrutiny of its own. Several members have disclosed professional ties to the peptide industry, including affiliations with companies that manufacture and sell injectable peptide products. Critics question whether such connections could influence the panel's ultimate recommendations.

Medical Experts Urge Patience Over Hype

For clinicians on the front lines, the disconnect between patient enthusiasm and scientific reality is a daily challenge.

"Not a day goes by where I don't have a number of patients asking me about peptides. My stock answer is that we just don't have enough data to support their use." — Dr. Alexander Weber, Orthopedic Surgeon and Chief of Sports Medicine, University of Southern California

Dr. Weber, who has conducted his own review of the available research, represents a broader consensus among medical professionals: the evidence base simply isn't there yet.

The FDA panel will examine proposed uses of these seven peptides for specific medical conditions, including ulcerative colitis, wound healing, obesity, and migraines. How the panel will reconcile their findings with the FDA scientists' stark conclusions remains to be seen — and the outcome could have significant implications for how these increasingly popular compounds are regulated going forward.